Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide maintenance in duodeno-pancreatic NETs
NCT02288377Phase 3Terminated
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2015
- Primary completion
- Jan 2020
- Modality
- Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in gastroenteropancreatic neuroendocrine tumor (GEP-NET) comparing Lanreotide with Placebo (2 arms). Primary endpoint: Proportion of Patients Alive and Progression-free at 6 months. Started Jan 2015; status: terminated.
02
Drugs
lanreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02288377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288377.